Annolyse
BriefingsCompaniesInsightsPrinciplesCompareWatchlist

Explore

  • Briefings
  • Companies
  • Insights
  • Compare

Resources

  • Search
  • Methodology
  • Developers

© 2026 Annolyse. Analytical briefings for NZX company announcements.

Table of contents

  1. What changed
  2. What matters
  3. Expectations
  4. Quality of result
  5. Unresolved
  6. Key metrics
  7. Segment breakdown
  8. Analytical metrics
  9. Metric context
  10. Reference material
←Back to briefings
Oceania Healthcare (OCA) / HY24

PBT swung NZD 64.9m to +$32.4m but revenue fell 24% on lower Village sales

Earnings recovery is real but structurally narrow: Village Operations deliver most of the profit on less than a fifth of revenue, while Care...

Release date
22 November 2023
Published
22 April 2026
Table of Contents⌄
  1. What changed
  2. What matters
  3. Expectations
  4. Quality of result
  5. Unresolved
  6. Key metrics
  7. Segment breakdown
  8. Analytical metrics
  9. Metric context
  10. Reference material

What changed

Revenue fell 24% to NZD $131.6m from $173.3m in HY23, driven almost entirely by a sharp contraction in Village Operations revenue (down from $52.3m to $25.1m). Care Operations, the largest revenue segment at 78% of group turnover, also declined from $121.0m to $102.7m. Despite the revenue fall, reported PBT swung from a loss of $32.5m to a profit of $32.4m — a $64.9m turnaround — and NPAT landed at $35.2m versus a prior-period loss of $24.1m. The NPAT figure sits slightly above PBT because HY24 attracted a $2.8m tax benefit rather than a charge; PBT is the cleaner read.

Underlying EBITDA was $37.6m, down modestly from $38.7m in the pcp — a 2.7% decline — suggesting the operating cost structure held reasonably well despite lower revenue.

Operating cash flow more than doubled to $48.0m from $23.7m. Gross borrowings rose to $621.4m, net debt to approximately $611.1m, and cash fell to $10.3m. Equity edged down 2.9% to $1b. No interim dividend was declared, versus 1.25 cents per share in HY23.

What matters

  • Village Operations earnings versus revenue asymmetry. Village Operations contributed only $25.1m or 19% of group revenue yet generated $56.4m of segment earnings — implying the group's profit recovery is heavily dependent on development and resale gains rather than recurring care income. The 38% uplift in new sale volumes (84 units) underpins this, but the revenue line does not yet reflect that volume improvement at the same scale as HY23, which raises questions about settlement timing and mix.

  • Trade receivables explosion. Receivables jumped from $11.0m to $121.5m, pushing implied receivable days from approximately 12 days to 168 days. This is the single largest working-capital development in the period and materially affects the quality of both the balance sheet and the operating cash flow improvement. In a retirement-village context this often reflects occupation right agreement settlements in transit or deferred receipt structures, but the scale of the movement — a 10x increase — warrants direct explanation that is not fully supplied in the available extract.

  • Leverage remains elevated relative to the earnings base. Net debt of approximately $611.1m against a half-year EBITDA run-rate of $37.6m implies an annualised net-debt-to-EBITDA of roughly 8x on an annualised basis. The company cites gearing of 37.7% and $113.9m in undrawn headroom, which provides near-term covenant comfort, but debt increased $55m during the half and equity declined, so the direction is adverse.

Expectations

No explicit forward guidance or quantified targets were disclosed in the supplied materials. In the absence of formal guidance, the prior-year shape provides limited but relevant context: HY23 represented 70% of FY23 revenue ($173.3m of $247.2m), suggesting the first half is structurally more revenue-weighted, likely reflecting settlement activity. HY24's $131.6m implies an annualised run-rate of approximately $263m, which is about 6.5% above FY23's $247.2m base — consistent with management's stated 8% increase in operating revenue versus the pcp of $122.1m.

The 38% uplift in new sale volumes to 84 units is a forward indicator, but the revenue and earnings translation will depend on when those settlements complete. With the FY23 EBITDA anchor at $80.0m and HY24 at $37.6m, the current run-rate is roughly on pace for a flat full-year outcome, though second-half village settlement activity could shift that materially in either direction.

The dividend suspension removes a cash obligation, which is consistent with the leverage reduction priority implied by the change in dividend policy (30%–50% of underlying EBIT) disclosed at FY23.

Quality of result

The PBT recovery is real in the sense that it reflects genuine village gains crystallised during the period, but it is not straightforwardly recurring:

  • Village Operations earnings of $56.4m are driven by development and resale margins that are transactional and lumpy by nature; they do not recur simply because the stock of residents turns over.
  • Care Operations, where recurring income is generated, contributed only $2.1m of segment earnings on $102.7m of revenue — a sub-2% margin that reflects the structural cost pressure in funded aged care.
  • The operating cash flow improvement to $48.0m is impressive on its face but must be read alongside the $110.5m surge in receivables, which would normally be a use of working capital. If receivables represent unconditional ORA receipts outstanding, cash quality is sound; if they reflect accrued income not yet contractually receivable, the quality is lower.
  • The effective tax rate of negative 8.6% (a benefit) means NPAT overstates the underlying earnings position versus a normalised tax rate; PBT of $32.4m is the appropriate anchor.
  • Capex for the current period was not disclosed in the available extract, preventing a free cash flow assessment — a material gap given the $113.3m of capex consumed in HY23.

Unresolved

  • Receivables composition. The $121.5m balance requires a breakdown between contractual ORA proceeds receivable, accrued care subsidies, and any other categories before the working-capital position can be properly assessed.
  • HY24 capex. Without capex disclosure, free cash flow is unknown. HY23 consumed $113.3m; even a materially lower HY24 figure would likely put free cash flow negative, conflicting with the headline operating cash improvement narrative.
  • Village revenue timing. Management reports 84 new sales with a 38% volume uplift, yet Village revenue fell from $52.3m to $25.1m. The gap between contracted sales and recognised revenue needs explicit reconciliation.
  • Care funding trajectory. Care Operations operating at sub-2% segment margin leaves no buffer for further funding shortfalls or cost inflation; the extract provides no read on government reimbursement rate movements or subsidy mix changes.
  • Debt covenant headroom detail. The $113.9m of undrawn headroom is cited but covenant definitions and thresholds are not disclosed, which matters given the leverage trajectory.

This briefing cannot assess whether the ORA receivable balance represents cash-secured settlements or accruals that may unwind, and therefore cannot confirm the quality of operating cash flow.

Key metrics

← Swipe to view more
Key metrics table for Oceania Healthcare HY24
Metric HY24 HY23 Change
Revenue $131.6m $173.3m -24.0% ↓
EBITDA $37.6m — —
Net profit after tax $35.2m −$24.1m +245.7% ↑
Net cash inflow from operating activities $48m $23.7m +102.4% ↑
Declared dividend per share 0.0c 1.3c -100.0% ↓
Profit before tax $32.4m −$32.5m +199.5% ↑
Cash and cash equivalents $10.3m $18.3m -43.6% ↓
Total assets $2.7b $2.5b +8.7% ↑

Segment breakdown

← Swipe to view more
Segment breakdown table for Oceania Healthcare HY24
Segment Current revenue Prior revenue Current result Mix shift
Care Operations $102.7m $121m $2.1m +8.2pp
Village Operations $25.1m $52.3m $56.4m -11.1pp
Other $3.9m — −$10.7m n/a

Analytical metrics

← Swipe to view more
Analytical metrics table for Oceania Healthcare HY24
Metric HY24 HY23 Context
Effective tax rate -8.6% n/m (loss period) prior loss period
OCF / EBITDA (cash conversion) 127.5% — stable
Capex — −$113.3m —
Debtor days 168.1 11.5 +156.6 days
Trade debtors $121.5m $11m +$110.5m
Net debt $611.1m $548.1m +$63m
Net debt / EBITDA 16.23x — Weakening
Gross borrowings $621.4m $566.3m +$55.1m
Payout ratio vs NPAT 0.0% — —
HY23 share of FY23 revenue 70.1% — Other half was 29.9%
HY23 share of FY23 NPAT -156.2% — Other half was 256.2%
Profit from continuing operations $35.2m — —

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.

Source-backed analysis from the filing set attached to this briefing.

Metric context

Trajectory before this result

A compact view of the company's recent revenue and margin path, derived from the same metrics history that powers the company page.

OCA revenue trajectory

Revenue context before the current result.

← Swipe to view more
OCA revenue trajectory preview table
PeriodOCA
HY26$131.6m
FY25$260.6m
HY25$132.6m
FY24$265.5m
HY24$131.6m
FY23$247.2m

OCA EBITDA margin

Earnings margin across covered periods.

← Swipe to view more
OCA EBITDA margin preview table
PeriodOCA
HY2631.5%
FY25n/a
HY2529.1%
FY2431.1%
HY2428.6%
FY2332.4%

Appendix

Reference material

Company materials considered in this briefing.

Current period

Interim Report

HY24 / financial report↗

Media Release

HY24 / media release↗

Results Announcement

HY24 / results announcement↗

Prior comparable period

Notice of Half Year Result Announcement

HY23 / financial report↗

Full-year context

Media Release

FY23 / financial report↗

Results Announcement

FY23 / results announcement↗

Related insight

See how cash conversion compares across covered companies

→

See how dividend coverage compares across covered companies

→

Email updates

Want briefings like this for the next reporting season?

Get the next Annolyse briefing by email when it is published.

OCA revenue trajectory

Revenue context before the current result.

OCA EBITDA margin

Earnings margin across covered periods.